Fighting mucopolysaccharidosis type I, a rare disease, by reprogramming B-cells

Immusoft to Present Data at ASGCT 2025, Demonstrating Positive Results from the World’s First Engineered B Cell in a Human Clinical Trial

Immusoft Goes For Cell Therapy Plan ‘B’

Safety and Initial Activity of Autologous Human B Cells Genetically Engineered to Express Human Iduronidase Using the Sleeping Beauty Transposon System: Results from a First-in-Human Clinical Trial in Subjects with MPS I

Results from a First-in-Human Clinical Trial in Subjects with MPS I

Immusoft to Present Positive Data from the First Engineered B Cell in a Human Clinical Trial at the 21st Annual WorldSymposium™ 2025

RARECast: Engineering B cells to Produce Therapeutic Proteins

MPS I Clinical Update and Outreach Webinar: Highlights

MPS I Clinical Update and Outreach Webinar

Immusoft Reports Promising Early Data for Lead Candidate in MPS I

First patient dosed with ISP-001 shows reduced urinary GAG level, functional improvements surpassing enzyme replacement therapy in Phase I trial

First patient who received engineered B cell therapy sees early promise for MPS I